<HashMap><database>biostudies-arrayexpress</database><scores/><additional><omics_type>Metabolomics</omics_type><omics_type>Unknown</omics_type><omics_type>Transcriptomics</omics_type><omics_type>Genomics</omics_type><omics_type>Proteomics</omics_type><submitter>Therese Sørlie</submitter><instrument_platform>Illumina NovaSeq X</instrument_platform><study_type>RNA-seq of coding RNA</study_type><organism>Homo sapiens</organism><species>Homo sapiens</species><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/E-MTAB-17490</full_dataset_link><description>FGFR1 is upregulated in a proportion of luminal breast cancer. This experiment investigates the role of FGFR1 in activating the cGAS-STING pathway.  Data include RNA sequencing of the tamoxifen-resistant T47D (TR-T47D) cell line after knock down by short hairpin RNA with and without treatment with the synthetic double-stranded DNA polymer poly(dA:dT). Sample set is comprised of 4 treatment groups and 4 replicates of each: ish-control +/- polyd(dA:dT), shFGFR1 +/- polyd(dA:dT).</description><repository>biostudies-arrayexpress</repository><sample_protocol>Library Construction - mRNA library preparation (poly A enrichment) by Novogene</sample_protocol><sample_protocol>Sample Collection - RNA extracted from in vitro cell cultures.</sample_protocol><sample_protocol>Nucleic Acid Extraction - RNA extraction by RNeasy isolation kit by Qiagen.</sample_protocol><sample_protocol>Sequencing - NovaSeq X Plus Series (PE150) by Novogene</sample_protocol><sample_protocol>Growth Protocol - TR-T47D shCTRL/shFGFR1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, GlutaMAX™ (2 mM), insulin (8 μg/ml), and maintained in 2 μg/ml puromycin to ensure stable shRNA expression.</sample_protocol><sample_protocol>Sample Treatment - Stable FGFR1 knockdown and control cells (TR-T47D shFGFR1, TR-T47DshCTRL) were generated by transduction with MISSION® shRNA lentiviral particles targeting FGFR1 (Sigma-Aldrich, Cat. #TRCN0000121185) and MISSION® pLKO.1-puro Non-Mammalian shRNA Control Transduction Particles  (Sigma-Aldrich, Cat. #SHC002V). Cells were transfected with lentiviral particles in Polybrene Infection / Transfection Reagent (Sigma-Aldrich, Cat. #TR-1003) according to the manufacturer's protocol. The cells were selected with 2 μg/mL of puromycin (Sigma-Aldrich, Cat. #P4512) after 48 hours of treatment with lentiviral particles. For Poly(dA:dT) transfections, cells were incubated with 5 µg/ml pre-complexed Poly(dA:dT)/LyoVec™ (InvivoGen, cat. no. tlrl-patc) for 24 h, with H₂O used as the control.</sample_protocol><figure_sub>Organization</figure_sub><figure_sub>MINSEQE Score</figure_sub><figure_sub>Assays and Data</figure_sub><figure_sub>MAGE-TAB Files</figure_sub><pubmed_authors>Therese Sørlie</pubmed_authors></additional><is_claimable>false</is_claimable><name>RNA sequencing data for knockdown of FGFR1 in TR-T47D cells</name><description>FGFR1 is upregulated in a proportion of luminal breast cancer. This experiment investigates the role of FGFR1 in activating the cGAS-STING pathway.  Data include RNA sequencing of the tamoxifen-resistant T47D (TR-T47D) cell line after knock down by short hairpin RNA with and without treatment with the synthetic double-stranded DNA polymer poly(dA:dT). Sample set is comprised of 4 treatment groups and 4 replicates of each: ish-control +/- polyd(dA:dT), shFGFR1 +/- polyd(dA:dT).</description><dates><release>2026-08-17T00:00:00Z</release><modification>2026-08-17T01:00:46.257Z</modification><creation>2026-08-13T19:36:02.25Z</creation></dates><accession>E-MTAB-17490</accession><cross_references><ENA>ERP203679</ENA><EFO>EFO_0002944</EFO><EFO>EFO_0004170</EFO><EFO>EFO_0003789</EFO><EFO>EFO_0005518</EFO><EFO>EFO_0003738</EFO><EFO>EFO_0004184</EFO><EFO>EFO_0003969</EFO></cross_references></HashMap>